* Ligand Pharmaceuticals Inc., of San Diego, discovered new tissue-selective male-hormone-based compounds that target the androgen receptor. The androgen receptor is a key molecular target that affects endocrine disorders and cancer.

* Ribi Immunochem Research Inc.., of Hamilton, Mont., acquired an exclusive, worldwide license to adjuvant technology from the Eppley Institute for Research in Cancer at the University of Nebraska Medical Center, in Lincoln.

No Comments